Mourabit Halima, Author at MediaMedic

Exploring Icosabutate for MASH: Insights from a Phase IIb Trial

By Mourabit Halima 2025.02.17

A recent phase IIb randomized trial, published in the Journal of Hepatology, evaluated Icosabutate, an oral FFAR1/FFAR4 agonist, in patients with biopsy-confirmed MASH and fibrosis (F1-F3). While the primary endpoint…

Advancing HCC Treatment: The Potential of Salsalate with Lenvatinib

By Mourabit Halima 2025.02.17

New research in JHEP Reports explores how Salsalate, a rheumatoid arthritis therapy, may enhance the effectiveness of Lenvatinib in treating MASH-driven hepatocellular carcinoma (HCC). By stimulating AMPK, enhancing fatty acid…

Immune Dysfunction and Infection Risk in Advanced Liver Disease

By Mourabit Halima 2025.02.17

The latest review in Gastroenterology explores the complex relationship between immune dysfunction and infection risk in advanced liver disease, highlighting the contributions of Brett McGettigan, Maria Hernandez-Tejero, Harmeet Malhi, and…

What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?

By Mourabit Halima 2025.02.17

The Journal of Clinical Oncology features an important discussion led by Neil Newman MD MS, Colin Court, MD, PhD, and Alexander Parikh, MD, MPH on the best locoregional treatment strategies…

Advancing Liver Cancer Care: Join the EASL Liver Cancer Summit 2025 in Paris

By Mourabit Halima 2025.02.17

The EASL Liver Cancer Summit 2025 will take place in Paris from February 20-22, bringing together leading experts to discuss the latest developments in liver cancer diagnosis, prognosis, and treatment.…

Final Results from the NATALEE Trial: Ribociclib in Early Breast Cancer

By Mourabit Halima 2025.02.15

New data from the NATALEE trial reinforce the efficacy of ribociclib in combination with endocrine therapy for HR-positive, HER2-negative early breast cancer. With a median follow-up of 33.3 months, the…

Latest Insights in HER2+ Early Breast Cancer: KATHERINE Trial Final Analysis

By Mourabit Halima 2025.02.15

New findings from the KATHERINE trial, published in The New England Journal of Medicine, confirm that trastuzumab emtansine (T-DM1) continues to provide superior survival benefits over trastuzumab alone in HER2-positive…

Professor Jun Ma: Advancing Frontiers, Updating Guidelines, and Accelerating the Globalization of Hematologic Cancer Treatment

By Mourabit Halima 2025.02.14

From January 17 to 19, 2025, the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Multiple Myeloma Expert Committee Meeting & 2025 CSCO Hematologic Oncology Conference was held in the scenic city of Haikou. This high-profile event brought together leading experts from China and abroad to discuss the latest advances in leukemia, lymphoma, and multiple myeloma, covering both fundamental research and clinical applications. The conference also addressed key challenges in diagnosis and treatment, fostering in-depth discussions among specialists.

Transarterial Chemoembolization (TACE) Combined with Camrelizumab and Rivoceranib Versus TACE Alone in Unresectable Hepatocellular Carcinoma

By Mourabit Halima 2025.02.14

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. For patients with unresectable HCC, transarterial chemoembolization (TACE) is a standard treatment. The phase 2, multicenter, open-label, randomized CARES-005…

$Voices from China at ESMO Asia: Dr. Rongbo Lin’s Team Reveals a Novel Treatment for Refractory Cancer Pain with Promising Potential to Improve Patient$

Voices from China at ESMO Asia: Dr. Rongbo Lin’s Team Reveals a Novel Treatment for Refractory Cancer Pain with Promising Potential to Improve Patient

By Mourabit Halima 2025.02.14

Editor's Note: Refractory cancer pain often responds poorly to standard pain management strategies. Both in vitro and in vivo studies have shown that hawthorn standardized extract (HSE) possesses central and…